What is Checkpoint Therapeutics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Checkpoint Therapeutics's interest expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Checkpoint Therapeutics's Operating Income for the
three
months ended in Mar. 2024 was $ -10.95 Mil. Checkpoint Therapeutics's Interest Expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
Checkpoint Therapeutics has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Checkpoint Therapeutics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Checkpoint Therapeutics (NAS:CKPT) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Checkpoint Therapeutics's Interest Expense for the
three
months ended in Mar. 2024 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-10.95 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $0.00 Mil.
Checkpoint Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| Checkpoint Therapeutics had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Checkpoint Therapeutics Inc has no debt.
Checkpoint Therapeutics (Checkpoint Therapeutics) Business Description
Traded in Other Exchanges
Address
95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in us. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).
Executives
| William Garrett Gray |
officer: See Remarks |
2 GANSEVOORT STREET,, 9TH FLOOR, NEW YORK NY 10014 |
| Oliviero James F Iii |
director, officer: CEO, President and Director |
C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
| Fortress Biotech, Inc. |
10 percent owner |
1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154 |
| Michael S Weiss |
director |
750 LEXINGTON AVE, NEW YORK NY 10022 |
| Neil Herskowitz |
director |
2109 BROADWAY, SUITE 206, NEW YORK NY 10023 |
| Christian Bechon |
director |
C/O LFB, 3, AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91940 |
| Barry M Salzman |
director |
464 COMMON STREET, SUITE 301, BELMONT MA 02478 |
| Scott Boilen |
director |
2 SKYLINE DRIVE, HAWTHORNE NY 10532 |
| Rosenwald Lindsay A Md |
director |
375 PARK AVE, NEW YORK NY 10152 |
| David J Horin |
officer: Interim CFO |
1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020 |
Checkpoint Therapeutics (Checkpoint Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CKPT has been successfully added to your 